Eptifibatide

• Description :

  Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity[1].

• CAS Number :

  [188627-80-7]

• UNSPSC :

  12352209

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Integrin

• Type :

  Peptides

• Related Pathways :

  Cytoskeleton

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Eptifibatide.html

• Purity :

  99.79

• Solubility :

  DMSO : 200 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

• Smiles :

  O=C(N(CCC1)[C@]1([H])C(N[C@@H](CSSCCC2=O)C(N)=O)=O)[C@](NC([C@@H](NC(CNC([C@@H](N2)CCCCNC(N)=N)=O)=O)CC(O)=O)=O)([H])CC3=CNC4=CC=CC=C34

• Molecular Formula :

  C35H49N11O9S2

• Molecular Weight :

  831.96

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Gilchrist IC, et al. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet. 2003;42 (8) :703-20.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Peptides

• Clinical Information :

  Launched